Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

2.280 UNCHANGED
Streaming Delayed Price Updated: 2:53 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vistagen Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Implement Board-Approved Reverse Stock Split
Via Investor Brand Network
Vistagen Announces Stockholder-Approved Reverse Stock Split
From Vistagen
Via Business Wire
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Presents Phase 3 SAD Study Results at ASCP Annual Meeting
Via Investor Brand Network
Vistagen Presents Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting
From Vistagen
Via Business Wire
Crude Oil Down 2%; Donaldson Shares Drop Following Q3 Results
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping over 100 points on Wednesday. The Dow traded down 0.34% to 32,929.04 while the NASDAQ fell 0.30% to 12,978.20. The S&P... 
Via Benzinga
Why Capri Holdings Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) shares jumped 143% to $0.45 after the company announced it received agreement from the FDA on its proposed single confirmatory Phase 3 study of... 
Via Benzinga
Nasdaq Down 100 Points; Advance Auto Parts Earnings Miss Views
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping over 100 points on Wednesday. The Dow traded down 0.82% to 32,773.27 while the NASDAQ fell 0.86% to 12,905.49. The... 
Via Benzinga
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) to Report Phase 3 Study Results at Upcoming ASCP Annual Meeting
Via Investor Brand Network
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why LL Flooring Shares Are Trading Higher By 19%; Here Are 20 Stocks Moving Premarket
Gainers VIQ Solutions Inc. (NASDAQ: VQS) shares rose 66.8% to $0.3887 in pre-market trading. 
Via Benzinga
Vistagen to Present Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting
From Vistagen
Via Business Wire
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Recognized with MHA Platinum Bell Seal for Workplace Mental Health
Via Investor Brand Network
Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health
From Vistagen
Via Business Wire
Vistagen Presents New Fasedienol (PH94B) Research at 2023 Anxiety and Depression Association of America Conference
From Vistagen
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Expands Portfolio with New European Patent for AV-101
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Why VistaGen Therapeutics Stock Is Trading Higher Today
VistaGen Therapeutics (NASDAQ: VTGN) shares are trading higher after the company announced it received a new European patent for AV-101. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Vistagen Receives New European Patent for AV-101
From Vistagen
Via Business Wire
Social Anxiety Disorder Impacts Around 23.7M People In US, Vistagen Releases Details Around Nasal Spray Treatment Program For It
Via Benzinga
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Receives Positive FDA Feedback Regarding Use of LSAS in Planned Phase 3 Study
Via Investor Brand Network
Exposures Product Safety
FDA Provides Positive Feedback to Vistagen Regarding Use of the Liebowitz Social Anxiety Scale (LSAS) as an Endpoint in Phase 3 Development of Fasedienol (PH94B) for Treatment of Social Anxiety Disorder
From Vistagen
Via Business Wire
Why VistaGen Therapeutics Shares Are Trading Higher Today
VistaGen Therapeutics (NASDAQ: VTGN) shares are trading higher on Wednesday after the company announced data from its Phase 3 open-label study evaluating safety and tolerability of fasedienol.  
Via Benzinga
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Positive Results from PH94B Phase 3 Study
Via Investor Brand Network
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Vistagen Announces Positive Data in Fasedienol (PH94B) Phase 3 Open-Label Study in Adults with Social Anxiety Disorder
From Vistagen
Via Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Provides Update on Phase 1 Clinical Trial of Proprietary PH10
Via Investor Brand Network
Vistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive Disorder
From Vistagen
Via Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Participate at Upcoming Health Care Conference
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.